---
title: CHI -- About us
description: Learn more about the team at CHI, their values and what drives them.
---
[Skip to content](https://chi.uk/about-us#main-content)
Close
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
SEARCH
[Contact us](https://chi.uk/about-us?hsLang=en#Contact)
[](https://chi.uk/home?hsLang=en)
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
[Contact us](https://chi.uk/about-us?hsLang=en#Contact)
# About us
## We are empowering a new era for respiratory medicine
We are designing DPI technology that will underpin the most effective inhalers in the world for generations to come. The work we are doing will deliver better outcomes for patients, across a broad range of therapies and diseases.
### We design and license revolutionary inhaler technology
- 01 Current situation
- 02 Our role
- 03 Reduced risk
- 04 Work with us
01 Current situation02 Our role03 Reduced risk04 Work with us
#### Patients deserve better
Pulmonary drug delivery is essential for the treatment of conditions like asthma and COPD, and it can revolutionise many other therapy areas including oncology, pain management, and immunisation. Delivering drug via the lungs has many advantages over parenteral and oral administration.
However, respiratory drug delivery has not been able to deliver on this promise. Existing devices on the market are often imprecise, and not easy to use correctly. **Innovation has been too slow** and the performance of inhalers on the market is inconsistent across patient groups, especially when many patients have compromised lung function.
#### The next generation of inhalers
**We offer the global pharmaceutical industry the next generation of DPIs, which will enable them to bring new therapies to patients.**
We provide device platforms that are highly effective and consistent, and are suitable for every stage of drug development to deployment.Our DPI platforms consistently deliver industry-leading performance, can be manufactured cost-effectively, and are easy to use for patients, overcoming limitations around compromised lung function.
These technologies will lead a new era for respiratory medicine, where devices will consistently deliver a high percentage of formulation to the patient’s deep lung.
#### Reducing the risks around getting your formulation to market
Each of our inhaler platforms is based around a **core engine**, enabling it to be designed into a range of device form factors, including single use, reusable, and multi-unit dose.
Because each core engine delivers robust and consistent performance, irrespective of its embodiment, pharmaceutical companies are able to use a single inhaler platform through development, testing, trials and launch. This **reduces the risks associated with drug product development**, as pharmacos can be certain that what they are seeing in the lab will match the real world when it is in the hand of a patient.
#### We license our platforms and build devices around them
We license our inhaler platforms to pharmaceutical companies who then use them through the later stages of drug development, through all phases of clinical trials, and then into the hands of patients.
Once tuned to our customer's formulation, the core engine is locked down. The outer form factor can then be adapted as needed, enabling us to quickly develop Phase I clinical devices and seamlessly progress to Phase II and Phase III device development, while maintaining consistent performance.
**We are not a fee-for-service consultancy company - we develop inhalers based on our core technology.**
## Our values
TOUCH
## Data-driven
## Data-driven
Our decisions are driven by data. We invent, experiment, and design, then rigorously test and validate our ideas. Reliable and predictable performance data is crucial for us and our clients to successfully bring devices based on our technology to market.
TOUCH
## Patient-focused
## Patient-focused
We design and develop technology to improve patients' lives. This focus has produced innovations with the potential to transform the lives of millions of patients each year.
TOUCH
## Science-based
## Science-based
Our deep understanding of the underlying physics ensures that our inventions are built upon solid scientific principles. This foundation leads to robust products that deliver optimal patient outcomes.
## Meet the team
We have a broad range of skills and a lot of experience when it comes to product design, engineering, respiratory physics, fluid dynamics, innovation, and technology licensing.
TOUCH
David Harris CEO & Co-founder
David has focused his 30-year career on the development of medical products, mainly in the field of respiratory drug delivery. He has more than 50 patent applications in the field, many of which have become part of commercially successful products.
[Read full bio](https://chi.uk/chi-blog/author/david-harris?hsLang=en)
David Harris CEO & Co-founder
TOUCH
Heather Jameson Senior Fluid Mechanics EngineerWith a PhD in Fluid Mechanics and several years' experience in medical and drug delivery design consultancy, Heather brings technical expertise and commercial insight to the team.[Read full bio](https://chi.uk/chi-blog/author/heather-jameson?hsLang=en)
Heather Jameson Senior Fluid Mechanics Engineer
TOUCH
Jamie Greenwood Principal Scientist
Jamie is a versatile scientist bringing over 22 years of technical leadership in medical product development. His approach is data-driven, combining thorough planning with careful execution, insightful data analysis and compliant reporting.
Jamie Greenwood Principal Scientist
TOUCH
Joel Williams Senior EngineerJoel is an enthusiastic mechanical engineer with experience designing medical devices and laboratory equipment. He brings technical expertise and experience in CAD and coding to the team.
Joel Williams Senior Engineer
TOUCH
Kate Naylor Office AdministratorKate joins CHI after spells at Cambridge University's Department of Biotechnology, the Institute for Manufacturing, CMR Surgical, and Kerio Technologies. As well as operational, marketing and project management skills, she also has experience within fast-growing tech companies.
Kate Naylor Office Administrator
TOUCH
Mike Oakes Co-founder & Non-executive DirectorA successful design engineer whose products have won critical acclaim and commercial success, Mike brings both commercial and technical support to the CHI team.[Read full bio](https://chi.uk/chi-blog/author/mike-oakes?hsLang=en)
Mike Oakes Co-founder & Non-executive Director
TOUCH
Neil Cooper Chief Operating OfficerNeil has spent his 25-year career within technology licensing, product development, and start-up companies. He brings his extensive commercial, strategic, and operational skills to CHI.[Read full bio](https://chi.uk/chi-blog/author/neil-cooper?hsLang=en)
Neil Cooper Chief Operating Officer
TOUCH
Sam Harris Laboratory Technician
Sam joined CHI as Lab Tech following technician roles at Oval Medical, Cambridge Consultants, CMR Surgical and Huber+Suhner Polatis.
Sam Harris Laboratory Technician
TOUCH
Simon Hubbard Principal Modelling & Simulation EngineerSimon has over 20 years' experience in applying computer aided engineering and optimisation techniques in industrial and consultancy environments, covering a range of applications including Formula One and Olympic cycling aerodynamics, inkjet printheads, temperature controlled packaging and inhalation devices.
Simon Hubbard Principal Modelling & Simulation Engineer
TOUCH
Warren Isaacs Principal EngineerWarren brings more than 30 years of mechanical and product design experience across a range of highly regulated industries, including medical, food and aviation.[Read full bio](https://chi.uk/chi-blog/author/warren-isaacs?hsLang=en)
Warren Isaacs Principal Engineer
.jpg?width=300&name=Pablo%20(1).jpg)
TOUCH
Pablo Expobar Senior Brew DeveloperPablo works in close collaboration with Luigi (Senior Bean Grinder) to bring liquid motivation to the team.
Pablo Expobar Senior Brew Developer
## Fostering excellence
We cultivate an environment that embraces diverse working styles and empowers individuals to excel. We also have a lot of fun.
TOUCH
Read More
TOUCH
Enlarge
TOUCH
Enlarge
TOUCH
Enlarge
TOUCH
Enlarge
TOUCH
Enlarge
TOUCH
Enlarge
TOUCH
Read More
TOUCH
Read More
TOUCH
Read More
## Our office
If you are in Cambridge and fancy a chat over a coffee, then you can find us on the Cambridge Science Park.
329 Cambridge Science Park
Milton Road
Cambridge CB4 0WG
UK
[info@chi.uk](mailto:info@chi.uk)
[Open Google Maps](https://maps.app.goo.gl/nEy6ZdEGUMMkfPyTA)
All rights reserved, Cambridge Healthcare Innovations Ltd 2026
- [Privacy policy](https://chi.uk/policies)
- Registered in England & Wales (GB11540827)
- [329 Cambridge Science Park, Cambridge CB4 0WG, UK](https://chi.uk/about-us#Contact)
```json
{
"@context" : "https://schema.org",
"@type" : "Organization",
"knowsLanguage" : "en",
"logo" : {
"@type" : "ImageObject",
"url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg"
},
"name" : "",
"url" : "https://chi.uk/about-us"
}
```